Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vanguard Russell 2000 Growth ETF (NQ:VTWG)

229.87 +3.61 (+1.60%)
Streaming Delayed Price Updated: 12:43 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard Russell 2000 Growth ETF

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study
After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 
Via Stocktwits
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
Via Stocktwits
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
Via Stocktwits
FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film
Via Stocktwits
Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate
Via Stocktwits
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a... 
Via Stocktwits
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail
Via Stocktwits
X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target
The company said that the originally announced offering of $60 million was increased to $85 million to allow for the inclusion of an investor who had a pre-existing investment right. 
Via Stocktwits
Topics Economy
CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock
The company is now poised to initiate late-stage trials for Neflamapimod. 
Via Stocktwits
This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why
Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.” 
Via Stocktwits
Topics Death
Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy
The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and... 
Via Stocktwits
Vanguard Has 10 Different Small-Cap Exchange-Traded Funds (ETFs). Which Should You Buy Right Now?
You might be surprised at how many ways you can passively invest in small-cap stocks. 
Via The Motley Fool
Fabrinet Q2: Earnings Beat, Moderated Datacom Demand, Expanded Stock Buyback & More
FN shares down premarket after reporting Q2 results, beating revenue and EPS expectations. Company remains optimistic, authorizes $100M buyback. 
Via Benzinga
Topics Earnings
Prediction: This Will Be the Top-Performing Index ETF in 2025
Via The Motley Fool
Topics ETFs
The Best Vanguard Small-Cap ETFs to Invest $500 in Right Now
Via The Motley Fool
Topics ETFs
Prediction: These 5 High-Flying Vanguard ETFs Will Trounce the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.